StreetAlpha.app
Home › Stocks › ENGN

enGene Therapeutics Inc. (ENGN)

$1.72
▼ −8.99%
LAST CLOSE · NOV 17

enGene Therapeutics develops genetic medicines, led by detalimogene, a product candidate for a type of bladder cancer. It last closed at $1.72 on Nov 17, down 8.99% on the day. ENGN reports earnings on Tue, Dec 22, 2026. The average 12-month price target from 3 analysts is $5.00 (+190.7% from the last close), with a high of $6.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ENGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$130.4M
Free cash flow
−$104.0M
Valuation
Market cap
$115.3M
67.0M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.0M
At Jul 31
Debt
$25.2M
At Jul 31
Shareholder equity
$230.3M
Shares outstanding
67.0M
At Sep 2
Fiscal year endsOctober
ExchangeNasdaq
Financials history
FY2022: −$24.5M−$24.5MFY2022FY2023: −$99.9M−$99.9MFY2023FY2024: −$55.1M−$55.1MFY2024FY2025: −$117.3M−$117.3MFY2025

From ENGN's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 8). Last 12 months adds up the four latest quarters.

Next report
Dec 22
2026 · Time not announced
Consensus EPS forecast
-$0.48
 
Year-ago EPS
-$0.73
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ENGN in the past 90 days
Average 12-month target
$5.00
▲ 190.7% upside

Based on 3 analysts who set a price target on ENGN in the past 90 days. The average target is $5.00, with a high of $6.00 and a low of $4.00, compared with the last close of $1.72.

Low $4.00Avg $5.00High $6.00
Blue marker: last close $1.72
Highest target$6.00
Average target$5.00
Lowest target$4.00
Latest rating changes
Leerink PartnersUpgrade
Nov 13Buy$5
Wells FargoUpgrade
Nov 12Buy$2 → $6
HC Wainwright & Co.Reiterated
Sep 8Buy$4
HC Wainwright & Co.Maintained
Jun 16Buy$4
Wells FargoDowngrade
May 8Hold$2
DateFirmActionRatingPrice target
Nov 13Leerink PartnersUpgradeBuy$5
Nov 12Wells FargoUpgradeBuy$2 → $6
Sep 8HC Wainwright & Co.ReiteratedBuy$4
Jun 16HC Wainwright & Co.MaintainedBuy$4
May 8Wells FargoDowngradeHold$2
Loading…

Technical Analysis

ENGN · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 125% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the swing low (Jul 29) at $1.71, and the nearest resistance the swing high (Oct 16) at $1.75.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$12.2552 week high+612.2%
$3.87200 day average+125.0%
$1.88Pivot R1+9.3%
$1.81100 day average+5.2%
$1.7950 day average+4.1%
$1.78Pivot+3.5%
$1.75Swing high (Oct 16)+1.7%
$1.7220 day average+0.0%
$1.72Last close
$1.71Swing low (Jul 29)−0.6%
$1.62Pivot S1−5.8%
$1.4052 week low−18.6%
Indicators
RSI (14)48.15Middle of its rangeNeutral
MACD0.07Above its signal lineBullish
Stochastic52.5Middle of its rangeNeutral
ADX (14)23.5Weak trend
Williams %R-74.5Oversold below −80, overbought above −20Neutral
CCI (20)26.1Oversold below −100, overbought above 100Neutral
Rate of change+6.2%Change over 10 sessionsBullish
ATR (14)$0.18Typical daily range, 10.7% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ENGN

What happened before

See how ENGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ENGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ENGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ENGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

ENGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼28 buying vs 34 selling
  • ▼Held by funds -1.1 pts
  • ▲Funds holding +2
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5856+3.6%
In funds' top 10110.0%
Held by funds56.4%57.5%−1.1 pts
New / increased17 / 1155 / 0−49.1%
Reduced / sold out19 / 150 / 1+3300.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENGN is in one of them and how their past ENGN trades turned out.

ENGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENGN in an article yet. Here's the latest on the wider market.

About enGene Therapeutics

enGene Therapeutics is a biotechnology company based in Saint-Laurent that develops genetic medicines. Its main product candidate, detalimogene, is intended for patients with a form of bladder cancer that no longer responds to BCG treatment. The company is also building a delivery platform that carries genetic medicines to mucosal tissues, with plans to apply it to other conditions such as urogenital and gastrointestinal diseases. Its products are still in preclinical and clinical development and are not yet approved for sale.

Headquarters
Saint-Laurent